Giampaolo Bianchini

Head Breast Cancer Group

IRCCS Ospedale San Raffaele

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Giampaolo Bianchini is the Head of the Breast Cancer Group at IRCCS Ospedale San Raffaele, Italy. His research focuses on the management and treatment of breast cancer, particularly in the areas of triple-negative and hormone receptor-positive breast cancers. Recent publications include studies on neoadjuvant therapy, the management of adverse events in metastatic cases, and the development of new clinical trial designs. His work aims to optimize therapeutic strategies and improve outcomes for patients with advanced breast cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

ITALY

View details

Lajos Pusztai

Yale University

UNITED STATES

View details

Christos Sotiriou

Université libre de Bruxelles

BELGIUM

View details

Kevin Kalinsky

Emory University

UNITED STATES

View details

KYONG HWA PARK

Associate Professor

Seoul National University Hospital

SOUTH KOREA

View details

ida paris

Head of Breast Oncology Unit

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

ITALY

View details

Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giampaolo Bianchini

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer

Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Collaborators (7)

Fabio Puglisi

Lajos Pusztai

Christos Sotiriou

Kevin Kalinsky

KYONG HWA PARK

ida paris

Sarah Sammons

Make your next move.